OncoMatch/Clinical Trials/NCT07827183
AI-Personalized Discharge Education for Patients After Lung Cancer Surgery
Official title: Effect of AI-Personalized Discharge Education on the Quality of Discharge Teaching and Recovery Outcomes in Patients After Lung Cancer Surgery: A Randomized Controlled Trial
Is NCT07827183 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for lung cancer (diagnosis).
This randomized controlled trial evaluates the effect of artificial intelligence (AI)-personalized discharge education on discharge teaching quality and recovery outcomes in patients after lung cancer surgery. Eligible participants will be randomly assigned in a 1:1 ratio to either an intervention group or a control group. The control group will receive routine discharge education, including verbal instructions and a standardized printed discharge booklet. The intervention group will receive the same routine education plus an AI-generated personalized discharge guidance plan based on individual clinical and care-related information. All AI-generated content will be reviewed by a responsible nurse before being provided to participants. The primary outcome is the quality of discharge teaching measured on the day of discharge. Secondary outcomes include self-efficacy for postoperative rehabilitation management and quality of life assessed one month after discharge.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Disease stage
Required: Stage I, II, III
Demographics
Prior therapy
Must have received: surgery — lung cancer
underwent radical lung cancer surgery by thoracoscopic or open approach, including lobectomy, pneumonectomy, or wedge resection
Cannot have received: targeted therapy
previous treatment with targeted therapy
Cannot have received: chemotherapy
previous treatment with chemotherapy
Cannot have received: radiation therapy
previous treatment with radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07827183 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior targeted therapy, chemotherapy, radiation therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify